Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) is -23.76% lower on its value in year-to-date trading and has touched a low of $35.24 and a high of $62.53 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CRNX stock was last observed hovering at around $40.59 in the last trading session, with the day’s loss setting it -1.61%.
Currently trading at $38.98, the stock is -24.01% and -29.08% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.9 million and changing -3.97% at the moment leaves the stock -23.68% off its SMA200. CRNX registered 3.67% gain for a year compared to 6-month gain of -27.37%. The firm has a 50-day simple moving average (SMA 50) of $55.3056 and a 200-day simple moving average (SMA200) of $51.09545.
The stock witnessed a -31.82% loss in the last 1 month and extending the period to 3 months gives it a -24.72%, and is -26.66% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.89% over the week and 5.28% over the month.
Crinetics Pharmaceuticals Inc (CRNX) has around 290 employees, a market worth around $3.61B and $0.00M in sales. Distance from 52-week low is 10.61% and -37.66% from its 52-week high. The company has generated returns on investments over the last 12 months (-31.65%).
with sales reaching $700k over the same period.The EPS is expected to shrink by -0.03% this year, but quarterly earnings will post -60.84% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Crinetics Pharmaceuticals Inc (CRNX) Top Institutional Holders
338.0 institutions hold shares in Crinetics Pharmaceuticals Inc (CRNX), with institutional investors hold 96.07% of the company’s shares. The shares outstanding are 92.74M, and float is at 86.88M with Short Float at 7.96%. Institutions hold 94.34% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 6.23 million shares valued at $279.06 million. The investor’s holdings represent 8.6187% of the CRNX Shares outstanding. As of 2024-06-30, the second largest holder is DRIEHAUS CAPITAL MANAGEMENT LLC with 6.11 million shares valued at $273.76 million to account for 8.4552 of the shares outstanding. The other top investors are WELLINGTON MANAGEMENT GROUP LLP which holds 4.62 million shares representing 6.3916% and valued at over $206.95 million, while VANGUARD GROUP INC holds 6.245 of the shares totaling 4.51 million with a market value of $202.2 million.
Crinetics Pharmaceuticals Inc (CRNX) Insider Activity
The most recent transaction is an insider sale by Pizzuti Dana, the company’s Chief Med and Dev Officer. SEC filings show that Pizzuti Dana sold 15,000 shares of the company’s common stock on Jan 03 ’25 at a price of $52.09 per share for a total of $0.78 million. Following the sale, the insider now owns 29248.0 shares.
Still, SEC filings show that on Dec 02 ’24, Struthers Richard Scott (President & CEO) disposed off 10,000 shares at an average price of $57.57 for $0.58 million. The insider now directly holds 100,000 shares of Crinetics Pharmaceuticals Inc (CRNX).
